Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
1.110
+0.070 (6.73%)
Nov 3, 2026, 3:09 PM EST - Market open

Cadrenal Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Income
-11.65-13.46-10.96-7.63-2.95
Net Income
-11.54-13.24-10.65-8.36-7.32
Earnings Per Share
-4.86-6.64-8.73-9.29-13.92
EPS Growth
-----

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
2.394.0110.028.40.03
Total Debt
---0.020.64
Net Cash (Debt)
2.394.0110.028.38-0.61
Net Cash Growth
-57.13%-59.99%19.53%--
Net Cash Per Share
1.012.018.219.32-1.16

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-10.16-12.6-7.36-3.53-1.31
Capital Expenditures
-0-0.01-0.01-0-0
Free Cash Flow
-10.16-12.61-7.36-3.53-1.32
Free Cash Flow Growth
-----

Valuation

Selected indicators aren't available for this stock.